Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
kaipharma.com

See what CB Insights has to offer

Executives

8

Board of Directors

2

KAI Pharmaceuticals Board of Directors

2 Board of directors

KAI Pharmaceuticals has 2 board of directors, including Abhijeet Lele.

Name

Firm

Work History

Other Seats

Abhijeet Lele

Abhijeet joined Investor Growth Capital as a Managing Director in April 2009. He is based in IGC’s New York office and focuses on investments in pharmaceutical and medical device companies. Before joining IGC, Abhijeet spent 10 years as a Managing Member of EGS Healthcare Capital Partners, a venture capital firm focusing on private and public investments in biotechnology, specialty pharmaceutical and medical device companies. Prior to EGS, Abhijeet was with the New York offices of McKinsey & Co., where he primarily served medical device, pharmaceutical and health insurance clients. He previously held operating positions with Lederle Laboratories, Progenics Pharmaceuticals and Clontech Laboratories. Abhijeet received an M.B.A. from Cornell University and an M.A. from Cambridge University, where he studied Natural Sciences. He currently serves as a board member of  Stereotaxis.

KAI Pharmaceuticals

Chris Ehrlich

Chris Ehrlich has been part of InterWest's life sciences team since 2000, focusing on investments in novel therapeutic approaches. He currently serves on the boards of two publicly owned companies: BioMimetic Therapeutics (BMTI) and Transcept Pharmaceuticals (TSPT). He also serves on the boards of several private companies, including: Carbylan BioSurgery, Follica, KAI Pharmaceuticals, QuatRx Pharmaceuticals, Satori Pharmaceuticals, Solace Pharmaceuticals, and Xenon Pharmaceuticals. Ehrlich played a role in InterWest's investment in Applied Genetic Technologies Corporation, and was involved with founding AlgoRx Pharmaceuticals, which merged with Anesiva (ANSV). Prior to joining InterWest, Ehrlich was director, licensing and business development at Purdue Pharma, a private pharmaceutical firm based in Stamford, CT. In this position, he was responsible for developing a biologic oncology franchise, including in-licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and participating in the commercial operations of Purdue BioPharma, a biotechnology company located in Princeton, NJ. Prior to joining Purdue, Ehrlich worked in business development at Genentech, in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at LEK Consulting. Ehrlich received his B.A. from Dartmouth College, cum laude, and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University where he serves as an instructor and advisor to the Biotech program. A Word from Chris "Over the past several years, I've had the opportunity to help a variety of new companies successfully commercialize their technologies. While providing strategic advice to medical technology startups, launching new entrepreneurial ventures in post-Soviet Russia, and in-licensing new biotechnologies for major biotech and pharmaceutical companies, I've learned a lot about what's required to transform great concepts into viable businesses. As a member of the Life Sciences team at InterWest, I have the opportunity to work alongside the scientists, technologists and physicians who are creating the future of healthcare &mdash

KAI Pharmaceuticals

Name

Abhijeet Lele

Chris Ehrlich

Firm

Work History

Abhijeet joined Investor Growth Capital as a Managing Director in April 2009. He is based in IGC’s New York office and focuses on investments in pharmaceutical and medical device companies. Before joining IGC, Abhijeet spent 10 years as a Managing Member of EGS Healthcare Capital Partners, a venture capital firm focusing on private and public investments in biotechnology, specialty pharmaceutical and medical device companies. Prior to EGS, Abhijeet was with the New York offices of McKinsey & Co., where he primarily served medical device, pharmaceutical and health insurance clients. He previously held operating positions with Lederle Laboratories, Progenics Pharmaceuticals and Clontech Laboratories. Abhijeet received an M.B.A. from Cornell University and an M.A. from Cambridge University, where he studied Natural Sciences. He currently serves as a board member of  Stereotaxis.

Chris Ehrlich has been part of InterWest's life sciences team since 2000, focusing on investments in novel therapeutic approaches. He currently serves on the boards of two publicly owned companies: BioMimetic Therapeutics (BMTI) and Transcept Pharmaceuticals (TSPT). He also serves on the boards of several private companies, including: Carbylan BioSurgery, Follica, KAI Pharmaceuticals, QuatRx Pharmaceuticals, Satori Pharmaceuticals, Solace Pharmaceuticals, and Xenon Pharmaceuticals. Ehrlich played a role in InterWest's investment in Applied Genetic Technologies Corporation, and was involved with founding AlgoRx Pharmaceuticals, which merged with Anesiva (ANSV). Prior to joining InterWest, Ehrlich was director, licensing and business development at Purdue Pharma, a private pharmaceutical firm based in Stamford, CT. In this position, he was responsible for developing a biologic oncology franchise, including in-licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and participating in the commercial operations of Purdue BioPharma, a biotechnology company located in Princeton, NJ. Prior to joining Purdue, Ehrlich worked in business development at Genentech, in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at LEK Consulting. Ehrlich received his B.A. from Dartmouth College, cum laude, and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University where he serves as an instructor and advisor to the Biotech program. A Word from Chris "Over the past several years, I've had the opportunity to help a variety of new companies successfully commercialize their technologies. While providing strategic advice to medical technology startups, launching new entrepreneurial ventures in post-Soviet Russia, and in-licensing new biotechnologies for major biotech and pharmaceutical companies, I've learned a lot about what's required to transform great concepts into viable businesses. As a member of the Life Sciences team at InterWest, I have the opportunity to work alongside the scientists, technologists and physicians who are creating the future of healthcare &mdash

Other Seats

KAI Pharmaceuticals

KAI Pharmaceuticals

KAI Pharmaceuticals Management Team

8 Team Members

KAI Pharmaceuticals has 8 executives. KAI Pharmaceuticals's current Chief Executive Officer, President is Steven P James.

Name

Work History

Title

Status

Steven P James

Chief Executive Officer, President

Current

Randolph M Johnson

Chief Technology Officer

Current

Stephen D Harrison

Senior Vice President

Current

Daniel A Carl

Chief Executive Officer

Former

Paul S Auerbach

Delphi Ventures

President, Chief Operating Officer

Former

Name

Steven P James

Randolph M Johnson

Stephen D Harrison

Daniel A Carl

Paul S Auerbach

Work History

Delphi Ventures

Title

Chief Executive Officer, President

Chief Technology Officer

Senior Vice President

Chief Executive Officer

President, Chief Operating Officer

Status

Current

Current

Current

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.